Life Sciences

  • November 13, 2025

    Claims Firms Accused Of Misleading Plaintiffs In Pharma MDL

    A Pennsylvania federal judge has been asked to slow down aggressive marketing campaigns from claims recovery firms that are accused of using false and misleading advertising to attract plaintiffs in a multidistrict litigation action against pharmaceutical companies.

  • November 12, 2025

    Biotech Co., Founders Can't Duck $14.3M SEC Payment

    A Colorado federal judge has rejected a biotech startup and two of its founders' bid to reconsider a February order requiring them to pay the U.S. Securities and Exchange Commission more than $14.3 million for overstating their own investments in the company.

  • November 12, 2025

    Valsartan Cancer Expert Blocked, Ending First Injury Trial

    What was set to be the first bellwether case in the sprawling multidistrict litigation over contaminated blood pressure medication Valsartan was decided Monday when a New Jersey federal judge excluded as "pure speculation" the plaintiff's medical expert who testified that the drug caused a patient's liver cancer.

  • November 12, 2025

    Sandoz Tells 3rd Circ. To Restore Full $137M Win Over UTC

    Sandoz Inc. and its marketing firm RareGen LLC urged a Third Circuit panel on Wednesday to reinstate the full $137.2 million awarded in breach of contract damages against United Therapeutics Corp., claiming a lower court's decision to halve the damages provided a windfall to their adversary.

  • November 12, 2025

    NJ Justices Keep Ozempic Injury Mass Torts Separate

    The New Jersey Supreme Court has decided not to combine two Bergen County Superior Court mass tort cases over weight loss drugs including Ozempic, Wegovy and Mounjaro, keeping them separate based on the type of injury alleged.

  • November 12, 2025

    Purdue Kicks Off Ch. 11 Confirmation With Plan Overview

    Bankrupt OxyContin maker Purdue Pharma began its Chapter 11 confirmation trial Wednesday with an overview of its latest plan and the myriad settlements that underpin the proposal, including a $6.5 billion commitment from the company's owners.

  • November 12, 2025

    Judge Confirms $620K Award In Radiology Contract Dispute

    A Georgia federal judge on Wednesday upheld a $620,000 arbitration award in favor of an Indian teleradiology company against a radiology provider, rejecting the latter's bid to vacate the decision by claiming an arbitrator misinterpreted their long-standing services agreement.

  • November 12, 2025

    1st Circ. Weighs Federal Halt To Planned Parenthood Funding

    First Circuit judges skeptically questioned a Planned Parenthood attorney Wednesday as they wrestled with whether Congress illegally singled out the organization in budget legislation that blocks its federal Medicaid funding for a year.

  • November 12, 2025

    China Continues To Drive Surge In Global Patent Applications

    The number of patent applications filed worldwide in 2024 surged, continuing years of growth due in significant part to filings out of China, according to a World Intellectual Property Organization report released Wednesday.

  • November 12, 2025

    China National Gets Time Served For Smuggling Crop Fungus

    A Chinese scholar with research ties to the University of Michigan will likely leave the United States this week after she was sentenced on Wednesday to time served following five months in custody for smuggling into the country a fungus that causes crop disease and lying about it to federal agents.

  • November 12, 2025

    Judge Won't Halt Injunction Blocking Trump's Trans Care Ban

    A Washington federal judge rejected the Trump administration's bid to halt a temporary injunction, saying the president took too long to request a pause in the order, which blocks federal officials from withholding federal healthcare funds to hospitals in four states that provide gender-affirming care. 

  • November 12, 2025

    Camp Lejeune Expert Criticism A Smear Tactic, Feds Say

    The U.S. government said Camp Lejeune toxic water litigants leaned on "empty accusations of bias" in an effort to exclude an expert witness, telling a North Carolina federal court that the expert has a decades-long track record of using reliable scientific methods.

  • November 12, 2025

    Jones Day, Paul Hastings Guide $9.3B Filtration Group Deal

    Parker-Hannifin Corp. has said it will acquire Filtration Group Corp. in a transaction valued at about $9.25 billion, expanding the industrial manufacturer's reach into recurring-revenue filtration systems used across industrial, life sciences and HVAC markets.

  • November 12, 2025

    Proposed Class Fights P&G Attempt To Transfer Tampon Case

    A proposed class alleging that Procter & Gamble tampons contain unsafe amounts of lead is urging a California federal court to reject the company's bid to transfer the case to Ohio federal court.

  • November 10, 2025

    Law360 MVP Awards Go To Top Attorneys From 76 Firms

    The attorneys chosen as Law360's 2025 MVPs have distinguished themselves from their peers by securing significant achievements in high-stakes litigation, complex global matters and record-breaking deals.

  • November 10, 2025

    GTCR's $627M Medical Coatings Acquisition Can Get Moving

    GTCR BC Holdings LLC can continue with its plan to acquire the nation's leading medical coatings supplier and merge it with the nation's second leading provider while federal regulators challenge the transaction in-house, an Illinois federal judge said Monday, refusing to halt the deal.

  • November 10, 2025

    IRhythm Denied Early Win On Investor Scienter & Loss Claims

    Heart monitor maker iRhythm Technologies cannot get an early win in a proposed investor class action alleging it made misleading disclosures about one of its devices, a San Francisco federal judge has determined.

  • November 10, 2025

    Pfizer Again Asks Judge To Toss States' Price-Fixing Case

    Pfizer has again asked a Connecticut federal judge to throw out claims it faces in a sprawling dermatology drug price-fixing lawsuit filed by multiple states against several pharmaceutical companies, arguing allegations against it were "scant and cursory."

  • November 10, 2025

    Medtech Co-Founder Tells Chancery Father-Son Cut Him Out

    A co-founder of a medtech company has sued in the Delaware Chancery Court alleging the two other co-founders, who are father and son, of engineering a covert squeeze-out aimed at stripping him of his 30% ownership stake just as the company approached a potentially lucrative fundraiser.

  • November 10, 2025

    Novartis Argues For High Court To Skip Entresto Patent Case

    Novartis Pharmaceuticals Corp. is urging the U.S. Supreme Court to skip MSN Pharmaceuticals Inc.'s request for review of a Federal Circuit decision that barred MSN's generic version of Novartis' blockbuster cardiovascular drug Entresto, asserting there is no conflict in the circuit for the justices to look at.

  • November 10, 2025

    FDA Lifts Hormone Replacement 'Black Box' Warnings

    The U.S. Food and Drug Administration on Monday said it was removing the "black box" warnings from hormone replacement therapy treatments for menopause for the risks of cardiovascular disease, breast cancer and probable dementia.

  • November 10, 2025

    FTC Risks Help Push Metsera Back To Pfizer

    Novo Nordisk AS' aspirations to pry Metsera away from Pfizer Inc. collapsed over the weekend under the pressure of a revised Pfizer offer, twin court challenges and "a call from the U.S. Federal Trade Commission."

  • November 10, 2025

    Chancery Drops Claims In Murder-Linked Bio Co. Merger Fight

    The Delaware Chancery Court dismissed a biotech company's claims against the husband and investment vehicle of convicted fraudster Serhat Gumrukcu, whose murder-for-hire plot allegedly helped conceal past misconduct ahead of a 2018 merger.

  • November 10, 2025

    Catching Up With Delaware's Chancery Court

    Delaware's top court issued a flurry of rulings last week and heard arguments on recently passed legislation that expanded liability shields for some corporate acts while the Court of Chancery passed on another round of arguments over control of Caribbean broadcaster Caribevision.

  • November 07, 2025

    4th Circ. Opioid Case Brings Public Nuisance Back To The Fore

    The Fourth Circuit's ruling that upturned a lower court win for drug distributors in a battle with the West Virginia county at the epicenter of the opioid epidemic was a blast from the past from the fever pitch of courtroom battles over the national crisis just a few years ago.

Expert Analysis

  • Organ Transplant System Reforms Mark Regulatory Overhaul

    Author Photo

    Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.

  • Adapting To USPTO's Reduction Of Examiner Interview Time

    Author Photo

    Reported changes to the U.S. Patent and Trademark Office's examiner performance appraisal plan will likely make interviews scarcer throughout the application process, potentially influencing patent allowance rates and increasing the importance of approaching each interview with a clear agenda and well-defined goals, say attorneys at Polsinelli.

  • Federal Grantees May Soon Face More Limitations On Speech

    Author Photo

    If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.

  • 5 Crisis Lawyering Skills For An Age Of Uncertainty

    Author Photo

    As attorneys increasingly face unprecedented and pervasive situations — from prosecutions of law enforcement officials to executive orders targeting law firms — they must develop several essential competencies of effective crisis lawyering, says Ray Brescia at Albany Law School.

  • Anticipating FTC's Shift On Unfair Competition Enforcement

    Author Photo

    As the Federal Trade Commission signals that it will continue to challenge unfair or deceptive acts and practices under Section 5 of the FTC Act, but with higher evidentiary standards, attorneys counseling healthcare, technology, energy or pharmaceuticals clients should note several practice tips, says Thomas Stratmann at George Mason University.

  • Insights From Recent Cases On Navigating Snap Removal

    Author Photo

    Snap removal, which allows defendants to transfer state court cases to federal court before a forum defendant is properly joined and served, is viewed differently across federal circuits — but keys to making it work can be drawn from recent decisions critiquing the practice, say attorneys at Perkins Coie.

  • Opinion

    It's Time For The Judiciary To Fix Its Cybersecurity Problem

    Author Photo

    After recent reports that hackers have once again infiltrated federal courts’ electronic case management systems, the judiciary should strengthen its cybersecurity practices in line with executive branch standards, outlining clear roles and responsibilities for execution, says Ilona Cohen at HackerOne.

  • Series

    Writing Novels Makes Me A Better Lawyer

    Author Photo

    Writing my debut novel taught me to appreciate the value of critique and to never give up, no matter how long or tedious the journey, providing me with valuable skills that I now emphasize in my practice, says Daniel Buzzetta at BakerHostetler.

  • SDNY OpenAI Order Clarifies Preservation Standards For AI

    Author Photo

    The Southern District of New York’s recent order in the OpenAI copyright infringement litigation, denying discovery of The New York Times' artificial intelligence technology use, clarifies that traditional preservation benchmarks apply to AI content, relieving organizations from using a “keep everything” approach, says Philip Favro at Favro Law.

  • What 9th Circ.'s Rosenwald Ruling Means For Class Actions

    Author Photo

    The Ninth Circuit's recent decision in Rosenwald v. Kimberly-Clark has important implications around the Class Action Fairness Act and traditional diversity jurisdiction — both for plaintiff-side and defense-side class action litigators — and deepens the circuit split concerning the use of judicial notice to establish diversity, says Grace Schmidt at DTO Law.

  • Trends In Post-Grant Practice Since USPTO Denial Guidance

    Author Photo

    Six months after the U.S. Patent and Trademark Office updated its guidance on discretionary denial of inter partes review and post-grant review, noteworthy trends in denial statistics have emerged, warranting a reassessment of strategies for parallel proceedings, says Andrew Ramos at Bayes.

  • USPTO Under Squires: A Look At The First Month

    Author Photo

    New U.S. Patent and Trademark Office Director John Squires' opening acts — substantive and symbolic — signal a posture that is more welcoming to technological improvements and focused on rebalancing the office's gatekeeping role, say attorneys at Seyfarth.

  • Opinion

    Expert Reports Can't Replace Facts In Securities Fraud Cases

    Author Photo

    The Ninth Circuit's 2023 decision in Nvidia v. Ohman Fonder — and the U.S. Supreme Court's punt on the case in 2024 — could invite the meritless securities litigation the Private Securities Litigation Reform Act was designed to prevent by substituting expert opinions for facts to substantiate complaint assertions, say attorneys at A&O Shearman.

  • Opinion

    High Court, Not A Single Justice, Should Decide On Recusal

    Author Photo

    As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Series

    Traveling Solo Makes Me A Better Lawyer

    Author Photo

    Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.